This supports previous findings showing that activation of insulin-mediated signalling pathways in glioblastoma promotes proliferation and survival of the tumour cells through PI3K/Akt [75] and anti-glycemic therapy has been recently shown to enhance PI3K inhibitor efficacy in glioblastoma patients [76]. Here, AKT1 is linked to neoplasm.